Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2007, Pages

  Vardi, Moshe ^a   Nini, A ^b  

^a CARMEL MEDICAL CENTER   (Israel)

^b NONE

Author keywords

3 ,5 Cyclic GMP phosphodiesterases *antagonists inhibitors ; Carbolines adverse effects; therapeutic use ; Cyclic nucleotide phosphodiesterases, type 5; Diabetic angiopathies *drug therapy

Indexed keywords

PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; VARDENAFIL;

ABNORMAL VISION; BACKACHE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DYSPEPSIA; EMBASE; ERECTILE DYSFUNCTION; FLU LIKE SYNDROME; FLUSHING; HEADACHE; HEART INFARCTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MEDLINE; MYALGIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RESPIRATORY TRACT DISEASE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; STREPTOCOCCUS INFECTION; TREATMENT OUTCOME;

EID: 44649172683     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002187.pub3     Document Type: Review

References (49)

1. Boulton 2001 {published data only} Boulton AJ, Selam JL, Sweeney M, Ziegler D. Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus. Diabetologia 2001;44:1296-301.
2. Escobar-Jimenez 2002 {published data only} Escobar-Jimenez F, Grupo de Estuido Espanol sobre Sildenafilo. Efficacy and safety of sildenafil in men with type 2 diabetes mellitus and erectile dysfunction [Eficacia y seguridad del sildenafilo en varones con diabetes mellitus tipo 2 y dysfuncion erectil]. Medicina clínica 2002;119:121-4.
3. Goldstein 2003 {published data only} Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003;26:777-83.
4. Price 1998 {published data only} Price DE, Gingell JC, Gepi-Attee S, Wareham K, Yates P, Boolell M. Sildenafil: study of novel oral treatment for erectile dysfunction in diabetic men. Diabetic Medicine 1998;15:821-5.
5. Rendell 1999 {published data only} Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction inmen with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999;281:421-6.
6. Saenz de Tejada 2002 {published data only} Saenz de Tejada I, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002;25:2159-64.
7. Safarinejad 2004 {published data only} Safarinejad MR. Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebo-controlled study. Diabetes Complications 2004;18:205-10.
8. Stuckey 2003 {published data only} Stuckey BG, Jadzinsky MN, Murphy LJ, Montorsi F, Kadioglu A, Fraige F, et al.Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care 2003;26:279-84.
9. Behrend 2005 Behrend L, Vibe-Petersen J, Perrild H. Sildenafil in the treatment of erectile dysfunction in men with diabetes: demand, efficacy and patient satisfaction. International Journal of Impotence Research 2005;17:264-9.
10. Carson 2005 Carson C, Shabsigh R, Segal S, Murphy A, Fredlund P. Efficacy, safety, and treatment satisfaction of Tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers. Urology 2005;65(2):353-9.
11. El-Sakka 2004 El-Sakka A. Efficacy of sildenafil citrate in treatment of erectile dysfunction: effect of type 2 diabetes. European Urology 2004;46:503-9.
12. Fonseca 2004 Fonseka V, Seftel A, Denne J, Fredlund P. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analyses of data from tadaladil clinical trials. Diabetologia 2004;47:1914-23.
13. Kalinchenko 1999 Kalinchenko SY, Kozlov GI, Melnichenko GA, Dedov II. Sildenafil citrate (Viagra) treatment in patients with diabetes. Terapevticheskii Arkhiv 1999;71:78-80.
14. Palumbo 2001 Palumbo F, Bettochi C, Selvagi FP, Pryor JP, Ralph DJ. Sildenafil: efficacy and safety in daily clinical experience. European Urology 2001;40:176-80.
15. Perimenis 2002 Perimenis P, Markou S, Gyftopoulos K, Athanasopoulos K, Giannitsas K, Barbalias G. Switching from lomg-term treatment with self-injections to oral sildenafil in diabetic patients with sever erectile dysfunction. European Urology 2002;41:387-91.
16. Salama 2004 Salama N. Nocturnal electrobioimpedence volumetric assessment in diabetic men with erectle dysfunction before and after Tadalafil intake. International Journal of Impotence Research 2004;16:441-7.
17. Vickers 2002 Vickers MA, Satyanarayana R. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. International Journal of Impotence Research 2002;14:466-71.
18. ADA 1997 American Diabetes Association. Report on the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20 Suppl 1:S5-20.
19. Andersson 1995 Andersson KE, Wagner G. Physiology of penile erection. Physiological Reviews 1995;75:191-236.
20. Bischoff 2004 Bischoff E. Vardenafil preclinical trial data potency, pharmacodynamics, pharmacokinetics, and adverse events. Interational Journal of Impotence Research 2004;16:S34-S37.
21. Christ 1995 Christ GJ. The penis as a vascular organ: the importance of corporal smooth muscle tone in the control of erection. Urologic Clinics of North America 1995;22:727-45.
22. Cialis presc info Cialis (tadalafil) prescribing information. Cialis (tadalafil) prescribing information. Indianapolis, IN, and Bothell, WA: Lilly ICOS LLC 2003.
23. Cohen 1960 Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement 1960;20:37-46.
24. Culley 2005 Culley CC. Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors. American Journal of Cardiology 2005;96:37M-41M.
25. Fugl-Meyer 1997 Fugl-Meyer AR, Lodnert G, Branholm IE. On life satisfaction in male erectile dysfunction. International journal of impotence research 1997;9:141-8.
26. Goldstein 1998 Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. New England Journal of Medicine 1998;338:1397-404.
27. Higgins 2002 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21:1539-58.
28. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
29. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd.
30. Jadad 1996 Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
31. Johannes 2000 Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men ages 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. The Journal of Urology 2000;163:460-3.
32. Kloner 2003 Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. American Journal of Cardiology 2003;92:47M-57M.
33. Kloner 2004 Kloner RA. Novel phosphodiesterase type 5 inhibitors assessing hemodynamic effects and safety parameters. Clinical Cardiology 2004;27:I20-I25.
34. Levita presc info Levitra (vardenafil) prescribing information. Levitra (vardenafil) prescribing information. West Haven, CT: Bayer Pharmaceutical Corporation 2003.
35. Lue 1988 Lue TF, Tanagho EA. Hemodynamics of erection. Contemporary Management of Impotence and Infertility. Baltimore, Williams & Wilkins, 1988:28-38.
36. Lue 2000 Lue TF. Erectile dysfunction. New England Jounal of Medicine 2000;342:1802-13.
37. McDonald 1996 McDonald LJ, Murad F. Nitric oxide and cyclic GMP signaling. Experimental Biology and Medicine 1996;211:1-6.
38. Mittleman 2003 MA, Glasser DB, Orazem J. Clinical trials of sildenafil citrate (Viagra) demonstrates no increase in risk of myocardial infarction and cardiovascular death compared with placebo. International Journal of Clinical Practice 2003;57:597-600.
39. Naylor 1998 Naylor AM. Endogenous neurotransmitters mediating penile erection. British Journal of Urology International 1998;81:424-31.
40. Nehra 1999 Nehra A, Barrett DM, Moreland RB. Pharmacotherapeutic advances in the treatment of erectile dysfunction. Mayo Clinic Proceedings 1999;74:709-21.
41. NIH Consensus 1993 NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993; Vol. 270:83-90.
42. Rajfer 1992 Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. New England Journal of Medicine 1992;326:90-4.
43. Rosen 1997 Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF). Urology 1997;49:822-30.
44. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;237:408-12.
45. Vinik 1998a Vinik AI, Richardson D. Erectile dysfunction in diabetes: pills for penile failure. Clinical Diabetes 1998;16:108-19.
46. Vinik 1998b Vinik AI, Richardson D. Erectile dysfunction in diabetes. Diabetes Reviews 1998;6:16-33.
47. WHO 1985 WHO Expert Committee on Diabetes Mellitus. World Health Organization, 1985. Technical Report Series 727.
48. WHO 1998 Alberti KM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its compliactions. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Medicine 1998;15:539-53.
49. Zusman 1999 Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate profile of sildenafil citrate. American Journal of cardiology 1999;83 Suppl:35C-44C.